NCT05030155

Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)

CompletedPHASE3INTERVENTIONAL

Trial Details

Start: 2022-05-30Est. Completion: 2025-02-21

Enrollment target: 102 participants

Locations

Service de Médecine Interne, Centre de référence " Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques "Hôpital Cochin, Paris, France

Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA)

This observational study aims to evaluate the long-term effectiveness and safety of mepolizumab 300 mg/4 weeks in adults…

Florence, ItalyCompleted Mar 31, 2026

AsthmaEosinophilic Granulomatosis With Polyangiitis (EGPA)Hypereosinophilic Syndrome (HES)

The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have…

Aurora, United StatesEst. completion Dec 27, 2029

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.